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Background and aim: Prolonged exposure to highly active antiretroviral therapy (HAART) is associated with
adverse effects such as hyperlactatemia. We determined the prevalence and risk factors for developing
hyperlactatemia among human immunodeficiency virus (HIV)-infected cameroonians on antiretroviral therapy (ART).
Methods: We conducted a cross-sectional study from January to April 2012 involving 91 HIV-infected patients
receiving ART for at least 12 months and 30 HIV-infected patients who have never received ART (ART-naïve
patients). Plasma lactate levels were determined after at least 12 hours of overnight fasting and hyperlactatemia
defined as lactate concentrations ≥ 3 mmol/L. The prevalence of hyperlactatemia was determined and the risk
factors were analyzed by a multivariate logistic regression model.
Results: The mean lactataemia was significantly higher in the group of HIV patients currently taking ART than in
the ART-naïve one (2.3 ± 1.3 and 1.7 ± 0.7 mmol/L respectively, p = 0.002). Patients on first line ART regimens had
significantly higher lactatemia than those on second line regimens (2.5 ± 1.5 and 1.9 ± 0.7 mmol/L respectively,
p = 0.014). The prevalence of hyperlactatemia in HIV patients receiving ART and in ART-naïve HIV patients was
respectively 18.7 and 6.7% (p = 0.095). ART-exposure (adjusted odds ratio (aOR) 5.44, 95% confidence interval (CI)
1.06 – 27.84; p = 0.042) and being on a first line regimen (aOR 16.22, 95% CI 1.57 – 167.91; p = 0.019) were
independent strong predictors of hyperlactatemia.
Conclusion: Hyperlactatemia was not rare in our study population. Being on a first line regimen constitutes an
important risk factor for developing hyperlactatemia. Measurement of plasma lactate may be useful in optimizing
the management of HIV-positive persons on ART.
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AIDS remains one of the major public health hazards in
Africa. The advent and widespread use of HAART in
clinical practice has profoundly modified the natural his-
tory of HIV infection by significantly improving the
prognosis and quality of life of people living with the infec-
tion, with a drastic reduction in mortality and morbidity
related to HIV and its complications [1]. Unfortunately,* Correspondence: movicky@yahoo.fr
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reproduction in any medium, provided the orthe need for permanent medication has led to increasingly
more numerous descriptions of new adverse metabolic ef-
fects, this being explained by mitochondrial toxicity [2]. It
has been demonstrated that this mitochondrial toxicity is
associated with hyperlactatemia, lactic acidosis, hepatic
steatosis, pancreatitis, lipodystrophy, and peripheral neur-
opathy [3].
Hyperlactatemia characterized by mild to moderate
increases in blood lactate levels in the absence of
acidosis has been reported in 8–36% of patients re-
ceiving HAART in developed countries, although the
majority of cases are asymptomatic or have very mild
symptoms [4-8]. Only a small number of patients de-
velop the most severe form of hyperlactatemia, whichal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a high mortality rate.
A variety of NRTIs, including stavudine, zidovudine
and didanosine, have been associated with hyperlactate-
mia because of their potential for mitochondrial toxic
effects [2,6,9-14]. While stavudine is rarely used in
resource-rich settings and is no longer recommended by
WHO for initial treatment of HIV-1 infection [14], it re-
mains an important component of standard ART regi-
mens in many resource-limited countries, mainly due to
its lower cost [15,16]. Some observational studies
have suggested that specific risk factors associated
with the development of hyperlactatemia include female
sex [17-23], elevated weight or BMI [17,20-23], older age
(> 40 years) [17,20], and lower CD4 cell counts [17].
There are limited data on hyperlactatemia caused by
prolonged exposure to ART in resource-limited settings
like Cameroon. The present study sought at determining
the prevalence and determinants related to the develop-
ment of hyperlactatemia in HIV-infected Cameroonians
currently on ART.Patients and methods
Study participants
This cross-sectional survey was carried out at the HIV
out-patient clinic of the Yaounde University Teaching
Hospital and the Yaounde Central Hospital. These cen-
ters are located in the political capital of Cameroon, and
receive a large number of HIV-infected patients living in
Yaounde and surrounding town. A convenient sample of
91 HIV-infected patients aged 18 years and above , cur-
rently on ART for at least 12 months and regularly
followed-up were consecutively enrolled in the study
during January – April 2012. These patients were receiv-
ing either first line regimen consisting of 2 NRTIs + 1
NNRTI, or second line regimen comprising 2 NRTIs + 1
PI. The choice of a particular regimen was irrespective
of potential factors that could induce hyperlactatemia
but depended mainly on the availability of ARTs. For
quality control purpose, a subset of 30 HIV-infected and
ART-naïve patients was also recruited. All the partici-
pants were confirmed to be positive for HIV antibody
through laboratory detection, and the diagnosis was in
line with national HIV/AIDS diagnosis criteria. They
were free of alcoholism, chronic hepatitis and were also
required not to be on plasma lactate modifying therapies
at their enrolment. All the procedures used in this study
were in accordance with the current revision of the
Helsinki Declaration. A Written and signed informed
consent was provided by all the subjects. Consent forms
and procedures, as well as survey protocol, were ap-
proved by the Cameroon National Ethics Committee
(Reference number: 234/CNE/SE/2011).Interview data
At enrollment standardized data collection forms were
completed, including sociodemographic characteristics,
medical history (AIDS events, CDC/WHO clinical clas-
sification, signs and symptoms of symptomatic hyperlac-
tatemia such as nonspecific gastrointestinal symptoms
nausea, vomiting, abdominal pain, discomfort or disten-
sion, anorexia, peripheral neuropathy, tiredness, muscle
weakness, and dyspnea [24]), laboratory markers (CD4
cell counts, FBS (Fasting Blood Sugar), AST (Aspartate
Amino Transferase) and ALT (Alanine Amino Transferase)
levels), and antiretroviral used.
Sample collection and biochemical assays
After at least 12 hours of overnight fasting and a 30 mi-
nutes rest, blood was aseptically collected from each par-
ticipant by venipuncture in a 5 ml EDTA tube, without a
tourniquet or fist clenching. Samples were put on ice
and immediately transported to the biochemistry labora-
tory where plasma specimens were separated by centri-
fugation at 3000 rpm within 5 min for analyses without
delay. Plasma lactate concentrations were determined on
an automated clinical chemistry analyzer (BA-88A,
MINDRAY laboratory, China) using kits (BIOREX
diagnostics, UK) based on the enzymatic conversion of
L-lactate to pyruvate by L-lactate oxidase [25].
End point definitions
Concentrations of plasma lactate less than 3 mmol/L
were defined as normolactatemic, while those equal or
above 3 mmol/L, were consider as hyperlactatemic.
Statistical analysis
Data were coded, entered, and analyzed using SPSS ver-
sion 20.0 (SPSS Inc., Chicago, Ilinois, USA). Qualitative
and quantitative variables were analysed and compared
with χ2 test and Student’s t-test respectively. Results are
expressed as proportion or mean ± SD. The Pearson cor-
relation was used to established the correlation between
the variables. ORs with 95% CIs were used to appreciate
the impact of different variables on the occurrence of
hyperlactatemia, and were calculated by both univariate
and multivariate logistic regression analyses while adjust-
ing for confounders. A p value < 0.05 was used to
characterize significant results.
Results
A total of 121 patients were included in this study including
91 HIV patients currently taking ART, and 30 ART-naïve
HIV patients. Table 1 presents the whole patient clinical
characteristics and biochemical determinations. The age
ranged from 25 to 67 years old (Mean = 40.3) for patients
under ART and between 24 to 64 years old (Mean = 38)
for naive ART patients. All the parameters recorded
Table 1 Clinical and biochemical characteristics of the study participants
Mean ± SD p
Patients on ART (n = 91) ART-naïve patients (n = 30) Overall (n = 121)
Age (years) 40.3 ± 9.9 38.5 ± 11.8 39.8 ± 10.4 0.327
Sex (Male/Female) 22/69 6/24 28/93 0.638
CDC Clinical Classification (A/C) 90/1 30/0 120/1 0.752
CD4 count (cells/mm3) 410.4 ± 231.9 261.8 ± 173.0 373.2 ± 226.9 0.192
AST (IU/L) 27.8 ± 15.9 25.6 ± 10.1 27.3 ± 14.6 0.171
ALT (IU/L) 25.6 ± 20.8 23.1 ± 8.3 24.9 ± 18.4 0.104
FPG (g/L) 0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.2 0.564
LDH (IU/L) 441.1 ± 138.1 485.1 ± 168.6 452.0 ± 146.8 0.253
Lactataemia (mmol/L) 2.3 ± 1.3 1.7 ± 0.7 2.2 ± 1.2 0.002*
Hyperlactatemic patients (%) 18.7 6.7 15.7 0.095
FBS: Fasting Blood Sugar; ALT: Alanine Amino Transférase, AST: Aspartate Amino Transférase, LDH: Lactate Dehydrogenase; * p<0.05.
Mamiafo et al. AIDS Research and Therapy 2014, 11:2 Page 3 of 8
http://www.aidsrestherapy.com/content/11/1/2were higher in the group of patients on ART therapy
compare to ART naïve except the level of LDH. There
was no statistically significant difference between the
two groups regarding all these parameters except lacta-
temia which was significantly (p < 0.005) higher in the
group of patients on ART (Table 1). Only classes A and
C of the CDC/WHO clinical classification of the HIV
infection were noticed. Figure 1 depicts the different
therapeutic regimens with the combination AZT –
3TC - NVP being the most recorded (32.97%). The first
line ART regimens was the most encountered (66%). How-
ever 25.27% of the patients were on LVP/r- TDF-3TC (sec-
ond line regimen). The mean lactataemia was significantlyFigure 1 Different therapeutic regimens the 91 ART-receiving subject
down the first line ones and the numbers refer to the number of subhigher in the group of HIV patients currently taking ART
than in the ART-naïve one (2.3 ± 1.3 and 1.7 ± 0.7 mmol/L
respectively) (Table 1). Nineteen over the one hundred
and twenty one participants (15.70%) presented with
hyperlactatemia; among them 17 were HIV patients cur-
rently taking ART (18.7%) and the 2 others (6.7%) being
ART-naïve patients (Table 1).
Table 2 compares clinical and biochemical parameters
between normolactatemic and hyperlactatemic patients
taking ART. We did not observe any statistically signifi-
cant difference between the two groups according to
age, sex, CD4+ T-cells count at time of hyperlactate-
mia, duration of cumulative ART exposure prior tos were placed on: up are represented second line regimens and
jects on each regimen.
Table 2 Characteristics of patients on ART with regard to the occurrence of hyperlactatemia
Normolactatemic n = 74
(Mean ± SD)
Hyperlactatemic n = 17
(Mean ± SD)
p
Age (years) 40.3 ± 9.4 39.9 ± 12.2 0.865
Sex (Male/Female) 16/58 6/11 0.189
CD4 count at time of hyperlactatemia (cells/mm3) 414.5 ± 230.8 392.8 ± 239.6 0.730
Duration of cumulative ART exposure prior to hyperlactatemia (years) 5.2 ± 2.9 4.5 ± 3.2 0.382
ART regimens
First line 44 16 0.007*
Second line 30 1
CDC/WHO Class
A 73 17 0.813
C 1 0
FPG (g/L) 0.9 ± 0.1 0.9 ± 0.2 0.220
AST (IU/L) 26.7 ± 12.0 32.8 ± 27.4 0.396
ALT (IU/L) 23.1 ± 11.4 36.6 ± 41.8 0.221
LDH (IU/L) 419.7 ± 107.9 534.3 ± 207.0 0.040*
Lactataemia (mmol/L) 1.8 ± 0.6 4.2 ± 1.8 < 0.001*
* p<0.05.
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mean serum LDH (Lactate Dehydrogenase), as well as
lactatemia, were significantly higher in the hyperlactate-
mic group (p = 0.040 and p < 0.001 respectively). Sixteen
patients (25.8%) on first line regimens significantly
develop hyperlactatemia (p = 0.007). Only one patient
on second line regimen (1.1%) presented with severe
hyperlactatemia.
Figure 2 is representative of the regimens that have led to
hyperlactatemia. There was no statistically significant differ-
ence when comparing the mean plasma lactate levels be-
tween these regimens. There was no correlation between
lactatemia and age (r = 0.023, p = 0.825), CD4+ T-cells
count (r = 0.071, p = 0.506), FBS (r = 0.151, p = 0.126), andFigure 2 Regimens that have given rise to hyperlactatemia.between lactatemia and serum LDH (r = 0.181, p = 0.085).
On the contrary, there was a positive and significant correl-
ation between lactatemia and AST (r = 0.439, p < 0.001),
and ALT (r = 0.544, p <0.001) (Table 3).
While undertaking univariate logistic regression ana-
lyses, we did not find any statistically significant associ-
ation between the occurrence of hyperlactatemia and the
sex (OR 2.25, 95% CI 0.789 – 6.42; p = 0.123), the dur-
ation of cumulative ART exposure (OR 2.59, 95% CI
0.87 – 7.72; p = 0.089), and between the occurrence of
hyperlactatemia and ART exposure (OR 3.22, 95% CI
0.70 – 14.93; p = 0.134) (Table 4). Nevertheless, this lat-
ter association became significant after adjusting for age,
sex and duration of ART exposure with a coefficient of
Table 3 Correlation between lactatemia and others
parameters
Variable P Pearson’s correlation
coefficient (r)
Age 0,825 0,023
CD4 count 0,506 0,071





Table 4 Factors likely to influence the occurrence of
hyperlactatemia
Odds ratio 95% CI p
Sex
Male 1.00
Female 2.25 0.79 – 6.42 0.130
Age groups (years)
20 – 29 1.00
30 – 39 0.42 0.07 – 2.57 0.347
40 – 49 0.67 0.11 – 4.15 0.664
≥ 50 0.21 0.02 – 2.84 0.243
Duration of cumulative
ART exposure
< 5 years 1.00
≥ 5 years 2.59 0.87 – 7.72 0.089
ART exposure
No 1.00
Yes 3.22 0.70 – 14.93 0.134
CDC clinical stage
A 1.19 1.1 – 1.28 0.843
C 1.00
ART regimen




Yes 1.02 0.32 – 3.32 0.969
First line TDF-regimens
No 1.00
Yes 1.17 0.35 – 3.97 0.797
First line 3TC-regimens
No 1.00
Yes 0.98 0.94 – 1.02 0.742
* p<0.05.
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p = 0.042), but after removing the duration of ART ex-
posure from the model, the last-mentioned association
was no more significant (aOR 4.09, 95% CI 0.82 – 20.33;
p = 0.085). Being on a first line ART regimen increased
more than 10 times the risk of developing hyperlactate-
mia (OR 10.91, 95% CI 1.37 – 86.70; p = 0.024), this risk
becoming more important after adjusting for age,
sex, and duration of ART exposure (aOR 16.22, 95% CI
1.57 – 167.91; p = 0.019) with a coefficient of determination
of 0.32. We finally observe no significant association be-
tween the occurrence of hyperlactatemia and zidovudine-
containing regimens, lamivudine-containing regimens, and
with tenofovir-containing regimens (Table 4).
Discussion
Lactate is the final product of anaerobic glycolysis,
which in a normal state does not accumulate in the
body. However, under circumstances such as oxygen
deprivation of tissue or impaired oxidative phosphoryl-
ation, hyperlactatemia occurs. Lactic acidosis in the ab-
sence of tissue ischemia is the hallmark of type B lactic
acidosis [26]. Among all anti-HIV medications, it is the
NRTIs that have been implicated in type B lactic acidosis
[26]. In fact, the pharmacologically active triphosphate
moieties of NRTIs act as substrates for human mito-
chondrial DNA-polymerase gamma, thereby having the
potential for incorporation into mitochondrial DNA
(mtDNA). As well, mitochondrial exonuclease is ineffi-
cient at removing the nucleoside triphosphates [27,28].
The combination of nucleoside triphosphate incorpor-
ation and inadequate removal disrupts mtDNA synthesis
and results in the arresting of mtDNA-encoded protein
synthesis. Eventually, a disruption of oxidative phosphor-
ylation ensues, and lactate accumulates [2].
Stavudine, zidovudine and didanosine are the most fre-
quent NRTIs incriminated in the occurrence of hyper-
lactatemia [2,6,9-14,29]. The combination of stavudine
and didanosine is associated with the greatest relative
risk [24]. In this study we had no patient placed on a
stavudine-containing regimens because stavudine has
been withdrawn from ART regimens recommended for
anti-HIV medications in Cameroon since 2011, mainly
due to its dyslipidemic effects proven in this milieu [30]
and in accordance with the latest WHO guidelines [14].
We observed in our study that zidovudine, lamivudine
and tenofovir were not implicated in the occurrence of
hyperlactatemia, probably because of the small sample
size and probably, the combination of all these nucleo-
side analogues would increase risk of adverse event de-
velopment. These findings concur with those from
Marceau et al. [29] where increased lactate was not asso-
ciated with treatment containing lamivudine, zidovudine,
abacavir, zalcitabine, efavirenz, nevirapine, and interferon
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second line regimen, we found lactatemia of patients on
first line regimens being significantly higher than that of
the ones on second line regimen. Furthermore, first line
regimen use may confer a sixteen-fold increased risk of
developing hyperlactatemia when controlling for other
risk factors. These findings can be explained by the fact
that PIs, which are part of second line regimen, have not
been reported to cause any mitochondrial toxicity [7]
given their lack of selectivity for HIV reverse transcript-
ase [14]. It has been also shown that the incidence and
prevalence of hyperlactatemia may vary depending on
the number and choice of NRTIs present in an anti-
retroviral regimen. In fact, in a longitudinal cohort
study involving 2144 patients receiving NRTI therapy,
the risk of symptomatic hyperlactatemia increased
more than 2-fold for each additional NRTI used in a
given regimen [31]. Different combinations of NRTIs
were also associated with different rates of symptomatic
hyperlactatemia [31].
We found significantly elevated plasma lactate levels
in patients currently taking ART compared to ART-
naïve ones, with an independent five-fold increased risk
for the subjects on ART for developing hyperlactatemia
when controlling for other covariates. But contrary to
John et al. [7] we did not observe any relationship be-
tween the occurrence of hyperlactatemia and duration of
cumulative ART exposure (especially stavudine in their
case). The Lactic Acidosis International Study group
[17], as well as Marceau et al. [32], showed an associ-
ation of older age (age > 40 years) with the development
of hyperlactatemia. This was not seen in our study nor
in some other ones [7,29,33] probably because our study
had a little bit younger age distribution than theirs
(mean of 40 years vs. 42 and 44 years respectively).
Moreover we found no relationship between the female
sex and the occurrence of hyperlactatemia. The same re-
sults were reported in others studies [7,29,33]. By con-
trast, some relevant studies have clearly demonstrated
that the female sex constitutes a strong independent risk
factor for developing hyperlactatemia [17-20,22,23,34,35],
even though the reasons for the observed sex differences
in rates of toxicity remain uncertain. As shown in other
studies, we observed no association between CD4+ T-cells
count, CDC/WHO clinical classification and the occur-
rence of hyperlactatemia [7,29,33].
There is no consensus on the different thresholds for
defining normolactatemia, mild to moderate hyperlacta-
temia (either symptomatic or not), and severe hyperlac-
tatemia. It has been proposed, from a clinical point of
view, that clinically relevant hyperlactatemia may be defined
as a lactate concentration of 2.25 – 5 mmol/L, and severe
lactic acidosis, as a lactate concentration > 5 mmol/L with a
pH < 7.3 or bicarbonate < 20 mmol/L and clinical signs ofmultiorgan failure [36]. In their study, Marceau et al.
[32], based on a previous determination of the refer-
ence interval for plasma lactate obtained from 200
healthy venous blood samples (range: 1.5 – 2.25 mmol/L;
mean ± SD: 1.4 ± 0.3 mmol/L) [32], defined concentrations
of plasma lactate < 2.25 mmol/L as normolactatemic,
those between 2.25 and 5 mmol/L as moderately in-
creased, and plasma lactate > 5 mmol/L was considered
highly increased. With these definitions, 75.2% of their pa-
tients were normolactatemic, 23% had moderately in-
creased serum lactate, and 1.8% had high serum lactate
giving thus an overall prevalence of hyperlactatemia
(plasma lactate ≥ 2.25 mmol/L) of 24.8% [32]. We had a
little bit more normolactatemic subjects than them (81.3%
vs. 75.2%) and less hyperlactatemic patients (18.7% vs.
24.8%) assumedly because our definition of normolactate-
mia was less restrictive than theirs (i.e. < 3 mmol/L vs. <
2.25 mmol/L). As we, they found that the mean value of
plasma lactate was significantly higher in the hyperlactate-
mic group than in the normolactatemic one [32].
The prevalence of asymptomatic hyperlactatemia re-
ported in resource-rich settings varies from one area to
another 8.3% [33], 8.7% [37], 18.3% [7] and 21% [4]. As a
matter of fact, the lack of a standard biochemical defin-
ition for lactic acidosis and symptomatic hyperlactatemia
causes confusion and affects incidence and prevalence
rates.
Nevertheless, it has been hypothesized that a lactate
measurement > 5 mmol/L is defined as severe hyperlac-
tatemia and therefore includes lactic acidosis [17,35].
Fabian et al. in South Africa [35] reported a prevalence
of severe hyperlactatemia of 1.3% corroborating our
1.1% even though a huge number of their patients were
on stavudine-based regimens.
Unfortunately, the cross-sectional design of the
present study could not permit us to determine the inci-
dence and time to onset of hyperlactatemia. Menezes
et al. [29] reported a median time to the development of
lactic acidosis of 10.8 months while Wester et al. [20] re-
ported a median time of 7.5 months. Moreover we were
unable to investigate for other risk factors incriminated
or not in the development of hyperlactatemia such as
higher baseline BMI (> 30 kg/m2), lower initial CD4+
T-cells count, higher baseline serum creatinine levels at
ART-initiation, this because these informations were
lacking in the majority of our patients’ files. It is unclear
whether and what extent symptomatic hyperlactatemia
might progress to lactic acidosis or whether they are two
completely separate disorders [7,37]. In fact, routine
monitoring of serum lactate levels does not appear to be
warranted [7]. Mild, asymptomatic elevations in lactate
levels have not been predictive of progression to lactic
acidosis [4,7], and a positive predictive value of only 39%
for the confirmation of lactic acidosis following a single
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count that lactic acidosis can present quite precipi-
tously and progress in a fulminant manner and those
patients can be relatively asymptomatic even with high
lactate concentrations, lactate levels should be mea-
sured as soon as clinical manifestations suggestive of
possible symptomatic hyperlactatemia occur in patients
currently taking ART. Marceau et al. [32] have pro-
posed that lactate measurements might be performed
every 6 months under standardized conditions in
asymptomatic patients to detect a trend of increasing
lactate concentrations.
Conclusion
Our results showed that chronic compensated and mod-
erated hyperlactatemia is common in ART-exposed HIV
infected Cameroonians. Even though stavudine is no
more part of ART-regimens, being on a first line regi-
men constitutes a strong and important risk factor for
developing hyperlactatemia. Early diagnosis of symptom-
atic hyperlactatemia by measurement of plasma lactate
under standardized conditions may allow safe outpatient
care and optimize the management of these HIV-
infected patients on ART.
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